Related Experiment Videos
Long-term hyposensitization and adverse immunologic responses. A laboratory evaluation.
Annals of Allergy
|June 1, 1985
Summary
Immunotherapy for allergic asthma and rhinitis did not alter immunoglobulin levels or autoimmune markers. However, a notable percentage of patients showed elevated antinuclear antibodies (ANA), suggesting a potential link warranting further investigation.
Area of Science:
- Immunology
- Allergology
- Autoimmunity
Background:
- Allergic asthma and rhinitis are common atopic conditions.
- Immunotherapy is a treatment for allergies.
- Autoimmune markers are sometimes monitored in patients with chronic conditions.
Purpose of the Study:
- To investigate the impact of immunotherapy on serum immunoglobulin concentrations and autoimmune markers in atopic patients.
- To compare these markers in patients with no prior immunotherapy, short-term immunotherapy, and long-term immunotherapy.
Main Methods:
- Quantitative determination of serum IgA, IgG, IgM, rheumatoid factor, C3, and C4 concentrations.
- Detection of antinuclear antibodies (ANA) and circulating immune complexes.
- Patients were divided into three groups based on immunotherapy duration.
Main Results:
- No statistically significant differences were observed in immunoglobulin levels, rheumatoid factor, C3, C4, or circulating immune complexes among the three groups.
- An elevated incidence of antinuclear antibodies (ANA) was found in 23.3% of the total patient cohort.
- No patients exhibited clinical signs or symptoms of autoimmune disease.
Conclusions:
- Long-term and short-term immunotherapy for allergic asthma and rhinitis does not appear to significantly affect key serum immunoglobulin and complement levels.
- The elevated prevalence of antinuclear antibodies (ANA) in atopic patients undergoing immunotherapy warrants further research to understand its clinical significance and potential implications.